Navigation Links
St. Jude Defines Eye Cancer Gene's Role in Retinal Development
Date:1/16/2008

Study provides the foundation for improving understanding of N-myc gene's role in the eyes' growth during fetal development when retinoblastoma forms

MEMPHIS, Tenn., Jan. 16 /PRNewswire-USNewswire/ -- A genetic discovery led by scientists at St. Jude Children's Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.

"A series of complex developmental processes must be carefully orchestrated for the eye to form correctly," said Michael Dyer, Ph.D., associate member in the St. Jude Department of Developmental Neurobiology. "One important aspect of this coordination is that retinal thickness be the same, irrespective of eye size. For example, the mouse eye is about 5,000 times smaller than that of the elephant eye, but the retinal thickness in these two species is comparable."

Working with mice, the researchers found that a gene called N-myc coordinates the growth of the retina and other eye structures to ensure the retina has the proper thickness necessary to convert light from the lens into nerve impulses that the brain transforms into images. Until their study, reported in the Jan. 15 issue of "Genes & Development," almost nothing was known about the molecular mechanisms responsible for properly sizing the retina. Dyer is the paper's senior author.

"This represents the first example of a role for a Myc gene in retinal development," Dyer said. "On the basis of our data, we propose that N-myc plays a central role in coordinating retinal proliferation with eye growth during development."

Genes in the Myc family carry out vital roles during prenatal development by regulating the proliferation, size, differentiation and survival of cells. Myc genes are also proto-oncogenes--genes in which a mutation enables them to transform normal cells
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Defines Regulatory Pathway for Adlea with FDA
2. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
5. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
6. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
7. Marital Status Doesnt Affect Lung Cancer Survival
8. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
9. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 ACIST Medical ... market leader of advanced imaging modalities for cardiology, showcased ... in two live cases at the Transcatheter Cardiovascular Therapeutics ... cases were presented from Medstar Washington Hospital Center ( ... University Medical Center ( New York, NY ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Mich., Oct. 19, 2011 Perrigo Company (Nasdaq: PRGO;TASE) ... agreement with Founder Pharma Co., Ltd., a wholly owned ... (SZSE: 000788).  Perrigo will supply infant formula manufactured in ... Pharma in China. Perrigo Chairman and CEO ...
... N.Y., Oct. 19, 2011  CureFAKtor Pharmaceuticals, LLC, a privately-held ... Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today ... will present a company overview at the Biotechnology Industry ... San Francisco, CA on Wednesday, October 26 at 9:00 ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Founder Group 2CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum 2
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Boston ... to create a monthly concert series, introducing young ... From the Top, America’s premier national platform celebrating ... musicians. Many of the young musicians featured will ... , “Boston Children’s Museum is fortunate to partner ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... New York City Department of,Health recently released a study ... obesity increased 17% over a two year period. With ... that they are,drinking sugar sweetened drinks with many calories, ... by drinking TrimWater, (http://www.trimwater.com )., TrimWater is a ...
... 29, 2008) Pauletta and Denzel Washington will present ... High School in Denzels hometown of Mount Vernon, N.Y. ... Pauletta and Denzel Washington Family Scholar in Neuroscience Awards ... of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles. ...
... of Queensland-based Astute Nanotechnology will celebrate the,achievements ... a special presentation and cocktail,reception tomorrow Tuesday, ... for industry partners to access the,expertise and ... of Excellence for Functional,Nanomaterials (ARC CFN). , ...
... 30 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc., (JPI), the Company engages in the ... supplement, and cosmetic products., AMDL today ...
... Psychemedics,Corporation (Amex: PMD ) today announced first ... The Company also announced a quarterly,dividend of $0.17 per ... 6,2008 to be paid on June 20, 2008. This ... Company,s revenue for the quarter ended March 31, 2008 ...
... Anthem,s Care Comparison Tool Gives Members in Wisconsin the ... Picture of Costs Associated with Medical Procedures, ... Blue Shield,in Wisconsin announced today the launch of its ... now nearly 3 million Anthem Blue Cross and Blue ...
Cached Medicine News:Health News:Time for New Yorkers to Drink Low-Calorie, Low-Sugar Flavored Water, TrimWater 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 3Health News:Astute Nanotechnology celebrates first year of success 2Health News:Astute Nanotechnology celebrates first year of success 3Health News:AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line 2Health News:Psychemedics Corporation Announces First Quarter Results 2Health News:Psychemedics Corporation Announces First Quarter Results 3Health News:Psychemedics Corporation Announces First Quarter Results 4Health News:Psychemedics Corporation Announces First Quarter Results 5Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 2Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 3
Plus cylinders only trial lens set....
This is a reduced form of the 100 Hue test and is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score. Kit includes 100 score pads....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Medicine Products: